Eloxx Pharmaceuticals, Inc. (ELOX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 34.41 Million USD | -47.86% |
| 2021 | 66.01 Million USD | 124.27% |
| 2020 | 29.43 Million USD | -41.77% |
| 2019 | 50.55 Million USD | 7.63% |
| 2018 | 46.97 Million USD | 145.92% |
| 2017 | 19.1 Million USD | 791.44% |
| 2016 | 2.14 Million USD | -43.45% |
| 2015 | 3.78 Million USD | -51.04% |
| 2014 | 7.73 Million USD | 10.21% |
| 2013 | 7.02 Million USD | 53.11% |
| 2012 | 4.58 Million USD | -13.31% |
| 2011 | 5.29 Million USD | -13.07% |
| 2010 | 6.08 Million USD | 22.05% |
| 2009 | 4.98 Million USD | 9.36% |
| 2008 | 4.55 Million USD | 12.43% |
| 2007 | 4.05 Million USD | 12.0% |
| 2006 | 3.62 Million USD | 3.87% |
| 2005 | 3.48 Million USD | 1.14% |
| 2004 | 3.44 Million USD | -14.98% |
| 2003 | 4.05 Million USD | 77.91% |
| 2002 | 2.27 Million USD | -1.54% |
| 2001 | 2.31 Million USD | 17.41% |
| 2000 | 1.97 Million USD | -19.46% |
| 1999 | 2.44 Million USD | 111.74% |
| 1998 | 1.15 Million USD | 11241.87% |
| 1997 | -10.37 Thousand USD | -32.83% |
| 1996 | -7810.00 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q2 | 4.14 Million USD | -24.49% |
| 2023 Q3 | 3.63 Million USD | -12.15% |
| 2023 Q1 | 5.48 Million USD | -9.04% |
| 2022 Q2 | 10.29 Million USD | -6.0% |
| 2022 Q4 | 6.02 Million USD | -15.6% |
| 2022 Q3 | 7.14 Million USD | -30.63% |
| 2022 FY | 34.41 Million USD | -47.86% |
| 2022 Q1 | 10.95 Million USD | -5.82% |
| 2021 Q4 | 11.63 Million USD | 13.52% |
| 2021 FY | 66.01 Million USD | 124.27% |
| 2021 Q1 | 8.41 Million USD | 45.52% |
| 2021 Q2 | 35.72 Million USD | 324.64% |
| 2021 Q3 | 10.24 Million USD | -71.33% |
| 2020 Q1 | 9.77 Million USD | -14.93% |
| 2020 Q4 | 5.78 Million USD | -8.16% |
| 2020 Q3 | 6.29 Million USD | -17.01% |
| 2020 FY | 29.43 Million USD | -41.77% |
| 2020 Q2 | 7.58 Million USD | -22.38% |
| 2019 FY | 50.55 Million USD | 7.63% |
| 2019 Q1 | 11.97 Million USD | -15.14% |
| 2019 Q2 | 14.31 Million USD | 19.49% |
| 2019 Q3 | 12.77 Million USD | -10.71% |
| 2019 Q4 | 11.48 Million USD | -10.1% |
| 2018 Q1 | 6.49 Million USD | 0.0% |
| 2018 FY | 46.97 Million USD | 145.92% |
| 2018 Q3 | 11.36 Million USD | -17.14% |
| 2018 Q2 | 13.71 Million USD | 111.15% |
| 2018 Q4 | 14.11 Million USD | 24.24% |
| 2017 Q1 | 341.88 Thousand USD | -32.63% |
| 2017 Q3 | 627.63 Thousand USD | 17.76% |
| 2017 FY | 19.1 Million USD | 791.44% |
| 2017 Q2 | 532.96 Thousand USD | 55.89% |
| 2016 Q3 | 760.24 Thousand USD | 9.15% |
| 2016 Q1 | 908.05 Thousand USD | -8.79% |
| 2016 Q2 | 696.51 Thousand USD | -23.3% |
| 2016 Q4 | 507.48 Thousand USD | -33.25% |
| 2016 FY | 2.14 Million USD | -43.45% |
| 2015 Q3 | 1.18 Million USD | 24.29% |
| 2015 Q2 | 956.52 Thousand USD | -24.24% |
| 2015 Q4 | 995.6 Thousand USD | -16.26% |
| 2015 Q1 | 1.26 Million USD | -51.91% |
| 2015 FY | 3.78 Million USD | -51.04% |
| 2014 Q4 | 2.62 Million USD | -9.31% |
| 2014 Q1 | 2.12 Million USD | 33.99% |
| 2014 Q3 | 2.89 Million USD | 76.87% |
| 2014 Q2 | 1.63 Million USD | -23.13% |
| 2014 FY | 7.73 Million USD | 10.21% |
| 2013 Q3 | 1.66 Million USD | 67.46% |
| 2013 FY | 7.02 Million USD | 53.11% |
| 2013 Q4 | 1.58 Million USD | -4.72% |
| 2013 Q2 | 995.81 Thousand USD | -4.64% |
| 2013 Q1 | 1.04 Million USD | -19.67% |
| 2012 Q2 | 1.24 Million USD | 12.32% |
| 2012 Q4 | 1.3 Million USD | 4.32% |
| 2012 FY | 4.58 Million USD | -13.31% |
| 2012 Q3 | 1.24 Million USD | 0.06% |
| 2012 Q1 | 1.1 Million USD | -33.05% |
| 2011 Q3 | 1.28 Million USD | 2.22% |
| 2011 Q2 | 1.25 Million USD | -8.44% |
| 2011 Q1 | 1.36 Million USD | -9.12% |
| 2011 Q4 | 1.65 Million USD | 29.37% |
| 2011 FY | 5.29 Million USD | -13.07% |
| 2010 Q4 | 1.5 Million USD | -31.76% |
| 2010 FY | 6.08 Million USD | 22.05% |
| 2010 Q3 | 2.2 Million USD | 27.58% |
| 2010 Q2 | 1.72 Million USD | 54.17% |
| 2010 Q1 | 1.12 Million USD | -2.75% |
| 2009 Q2 | 1.22 Million USD | 14.13% |
| 2009 FY | 4.98 Million USD | 9.36% |
| 2009 Q4 | 1.15 Million USD | 17.2% |
| 2009 Q3 | 983.71 Thousand USD | -19.66% |
| 2009 Q1 | 1.07 Million USD | -12.67% |
| 2008 FY | 4.55 Million USD | 12.43% |
| 2008 Q3 | 1.03 Million USD | 5.05% |
| 2008 Q4 | 1.22 Million USD | 18.77% |
| 2008 Q2 | 984.48 Thousand USD | -27.14% |
| 2008 Q1 | 1.35 Million USD | 38.14% |
| 2007 FY | 4.05 Million USD | 12.0% |
| 2007 Q4 | 978.1 Thousand USD | 31.83% |
| 2007 Q1 | 828.48 Thousand USD | -38.31% |
| 2007 Q2 | 756.89 Thousand USD | -8.64% |
| 2007 Q3 | 741.95 Thousand USD | -1.97% |
| 2006 Q4 | 1.34 Million USD | 93.9% |
| 2006 Q3 | 692.63 Thousand USD | -14.74% |
| 2006 Q2 | 812.38 Thousand USD | 4.49% |
| 2006 Q1 | 777.44 Thousand USD | -18.52% |
| 2006 FY | 3.62 Million USD | 3.87% |
| 2005 Q3 | 941.99 Thousand USD | 46.5% |
| 2005 Q2 | 642.98 Thousand USD | -31.2% |
| 2005 FY | 3.48 Million USD | 1.14% |
| 2005 Q4 | 954.18 Thousand USD | 1.29% |
| 2005 Q1 | 934.52 Thousand USD | 4.33% |
| 2004 Q2 | 780.45 Thousand USD | 26.97% |
| 2004 Q1 | 614.68 Thousand USD | -31.6% |
| 2004 Q3 | 743.98 Thousand USD | -4.67% |
| 2004 Q4 | 895.74 Thousand USD | 20.4% |
| 2004 FY | 3.44 Million USD | -14.98% |
| 2003 Q2 | 487.23 Thousand USD | -8.43% |
| 2003 Q3 | 1.41 Million USD | 189.67% |
| 2003 FY | 4.05 Million USD | 77.91% |
| 2003 Q4 | 898.67 Thousand USD | -36.33% |
| 2003 Q1 | 532.09 Thousand USD | -25.28% |
| 2002 Q1 | 495.49 Thousand USD | -43.46% |
| 2002 Q3 | 547.18 Thousand USD | 23.08% |
| 2002 Q4 | 712.08 Thousand USD | 30.14% |
| 2002 FY | 2.27 Million USD | -1.54% |
| 2002 Q2 | 444.59 Thousand USD | -10.27% |
| 2001 Q3 | 497.72 Thousand USD | 25.13% |
| 2001 Q2 | 397.76 Thousand USD | -13.71% |
| 2001 Q4 | 876.42 Thousand USD | 76.09% |
| 2001 FY | 2.31 Million USD | 17.41% |
| 2001 Q1 | 460.96 Thousand USD | -21.24% |
| 2000 FY | 1.97 Million USD | -19.46% |
| 2000 Q3 | 527.08 Thousand USD | -16.07% |
| 2000 Q4 | 585.25 Thousand USD | 11.04% |
| 2000 Q1 | 827.37 Thousand USD | 65.48% |
| 2000 Q2 | 627.99 Thousand USD | -24.1% |
| 1999 Q4 | 500 Thousand USD | 0.0% |
| 1999 FY | 2.44 Million USD | 111.74% |
| 1998 FY | 1.15 Million USD | 11241.87% |
| 1997 FY | -10.37 Thousand USD | -32.83% |
| 1996 FY | -7810.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| America Great Health | 661.23 Thousand USD | -5105.283% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -271.375% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -14.757% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 48.741% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -117.251% |
| Better Therapeutics, Inc. | 38.26 Million USD | 10.044% |
| Calithera Biosciences, Inc. | 40.68 Million USD | 15.41% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -177.735% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -1.699% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 68.267% |
| Evolutionary Genomics, Inc. | 992.8 Thousand USD | -3366.83% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -5.615% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 26.692% |
| Innovation1 Biotech Inc. | 1.21 Million USD | -2733.567% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -72.619% |
| Molecular Templates, Inc. | 63.09 Million USD | 45.445% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | -147.057% |
| NexImmune, Inc. | 28.16 Million USD | -22.194% |
| Orgenesis Inc. | 45.75 Million USD | 24.779% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -34.203% |
| Point of Care Nano-Technology, Inc. | 73.41 Thousand USD | -46782.151% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -113.183% |
| Scopus BioPharma Inc. | 11.71 Million USD | -193.806% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 91.471% |
| Statera Biopharma, Inc. | 28.82 Million USD | -19.388% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -81.832% |
| Trevena, Inc. | 38.41 Million USD | 10.398% |
| Vaxxinity, Inc. | 56.05 Million USD | 38.593% |
| Vaccinex, Inc. | 23.45 Million USD | -46.745% |
| Vicapsys Life Sciences, Inc. | 1.04 Million USD | -3187.462% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 32.103% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -373.138% |